Long‐term efficacy and safety of dose‐dense and dose‐intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15‐year follow‐up of the ABVDDD‐DI phase II study

Summary We demonstrated that dose‐densified and dose‐intensified ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVD DD‐DI ) was safe and effective. Here, we present a post hoc long‐term analysis of the 82 patients enrolled in the original study. The median observation time was 175 months (IQR 159–197). At 15 years, progression‐free and overall survival rates were 81.2% (95% CI, 69.9%–88.7%) and 92.7% (95% CI, 82.6%–97.0%), respectively. Four patients with multiple cardiovascular risk factors experienced delayed G3 cardiac events. The cumulative incidence of second malignancies at 20 years was 6.1%. Fertility and childbearing potential were unaffected. Data support an ongoing benefit for ABVD DD‐DI without uneven late toxicities.